Jazz PharmaceuticalsHAM:J7Z +4.91%73 OCF Yield % is 8.93 as of Jul. 01, 2026, which is 13% below its 10-year median of 10.27. GuruFocus rates HAM:J7Z with a GF Score™ of 73/100 and a GF Value™ of €127.01 (Significantly Overvalued). The stock has 6 warning signs investors should review. Among 1,416 Biotechnology companies, Jazz Pharmaceuticals ranks better than 94.7% on this metric.
OCF Yield % is calculated as Cash Flow from Operations divided by Market Capitalization. It is a financial solvency ratio that compares the operating cash flow a company is expected to earn against its market value.
Similar to Earnings Yield %, OCF Yield % is financial solvency ratio. A lower ratio suggests a less attractive investment, indicating that investors might not receive substantial returns in proportion to their investment. Conversely, a high operating cash flow yield signals that a company generates sufficient cash to comfortably meet its debts, obligations, and dividend payments, making it a promising investment choice.
Jazz Pharmaceuticals OCF Yield % Related Terms
Jazz Pharmaceuticals OCF Yield % Historical Data
* Premium members only.
The historical data trend for Jazz Pharmaceuticals's OCF Yield % can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
HAM:J7Z vs BBIO, EXEL, IONS: OCF Yield % Comparison
For the Biotechnology subindustry, Jazz Pharmaceuticals's OCF Yield %, along with its competitors' market caps and OCF Yield % data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Jazz Pharmaceuticals OCF Yield % vs Biotechnology Industry
For the Biotechnology industry and Healthcare sector, Jazz Pharmaceuticals's OCF Yield % distribution charts can be found below:
* The bar in red indicates where Jazz Pharmaceuticals's OCF Yield % falls into.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Jazz Pharmaceuticals (HAM:J7Z) has a OCF Yield % of 8.93 as of Jul. 01, 2026. OCF Yield is calculated as Cash Flow from Operations divided by Market Capitalization. View historical data on Jazz Pharmaceuticals and its competitors. This is 13% below median its historical median of 10.27. Over the past decade, Jazz Pharmaceuticals' OCF Yield % has ranged from 6.12 to 26.13. According to the industry distribution chart, Jazz Pharmaceuticals ranks #75 out of 1416 companies in the Biotechnology industry, placing it in the top 5.3%.
Is Jazz Pharmaceuticals' OCF Yield % too high?
Jazz Pharmaceuticals' current OCF Yield % of 8.93 is 13% below median its 10-year median of 10.27. Over the past 10 years, this metric has ranged from a low of 6.12 to a high of 26.13. Based on the distribution chart, Jazz Pharmaceuticals ranks #75 out of 1416 companies in the Biotechnology industry, which is in the top quartile — a strong position relative to peers. Overall, Jazz Pharmaceuticals has a GF Score™ of 73/100 and is considered Significantly Overvalued, reflecting its overall financial health beyond just this single metric.
How does Jazz Pharmaceuticals' OCF Yield % compare to BBIO and EXEL?
According to the Biotechnology industry distribution chart, Jazz Pharmaceuticals ranks #75 out of 1416 companies for OCF Yield %. This places Jazz Pharmaceuticals in the top 5% of its industry — outperforming the majority of peers. Historically, Jazz Pharmaceuticals' own OCF Yield % has ranged from 6.12 to 26.13 over the past decade. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good OCF Yield % for a Biotechnology company?
A good OCF Yield % depends on the Biotechnology industry context. However, OCF Yield % should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high OCF Yield % mean?
A high OCF Yield % can signal that a stock is expensive relative to its fundamentals. OCF Yield is calculated as Cash Flow from Operations divided by Market Capitalization. View historical data on Jazz Pharmaceuticals and its competitors. Jazz Pharmaceuticals's current OCF Yield % is 8.93, which is 13% below median its own 10-year median of 10.27. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Jazz Pharmaceuticals stock overvalued right now?
Based on GuruFocus' analysis, Jazz Pharmaceuticals (HAM:J7Z) is currently considered Significantly Overvalued. The stock's GF Value™ is €127.01, compared to a current price of €209.50 — trading 64.9% above its estimated fair value. The current OCF Yield % is 8.93, which is 13% below median its 10-year median of 10.27. Jazz Pharmaceuticals' overall GF Score™ is 73/100 with 6 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is OCF Yield % calculated?
OCF Yield % is calculated from a company's financial statements. For Jazz Pharmaceuticals (HAM:J7Z), the current OCF Yield % is 8.93 as of Jul. 01, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Jazz Pharmaceuticals (HAM:J7Z) Overvalued in 2026?
Based on GuruFocus' analysis, Jazz Pharmaceuticals stock appears to be overvalued.
The current stock price of €209.50 is trading 64.9% above its estimated GF Value™ of €127.01.
GuruFocus considers Jazz Pharmaceuticals to be Significantly Overvalued.
Key valuation signals for HAM:J7Z:
OCF Yield %: 8.93 (13% below median its 10-year median of 10.27)
GF Value™: €127.01 vs. price of €209.50 (64.9% above fair value)
No single metric tells the full story. See the HAM:J7Z stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Jazz Pharmaceuticals is an Ireland-domiciled biopharmaceutical firm focused primarily on treatments for sleeping disorders and oncology. Jazz has nine approved drugs across neuroscience and oncology indications; its portfolio includes Xyrem and Xywav for narcolepsy, Zepzelca for the treatment of metastatic small cell lung cancer, Rylaze for acute lymphoblastic leukemia, and Vyxeos for acute myeloid leukemia. In May 2021, Jazz acquired GW Pharmaceuticals and gained its leading product, Epidiolex for the treatment of severe, rare forms of epilepsy.
73GF Score
Get the complete analysis for HAM:J7Z
OCF Yield % is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
HAM:J7Z has been successfully added to your 
